MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$48M
Free Cash flow
$222M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Net income
Other current and noncurrent lia...
Deferred income taxes
Others
Negative Cash Flow Breakdown
Cash paid for repurchases of com...
Other current and noncurrent ass...
Purchases of property and equipm...
Purchases of investments in debt...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
122
89
102
43
Depreciation and amortization
2
2
2
3
Amortization of right-of-use assets
1
2
3
2
Stock-based compensation
11
9
5
7
Impairment of tangible and intangible assets
2
6
3
16
Loss on debt extinguishment
0
-18
-
-
Unrealized loss on equity investments
0
-
1
0
Deferred income taxes
25
27
-38
-15
Acquired in-process research and development
-
-
0
0
Impact from foreign exchange movements
-1
0
-3
-3
Amortization of debt issuance costs
1
-
-
-
Other adjustments, net
0
2
-
-1
Accounts receivable
-3
20
-6
18
Current inventories
-4
1
-2
6
Other current and noncurrent assets
17
18
-11
-7
Accrued legal and settlement expenses
1
-38
-310
2
Other current and noncurrent liabilities
73
-86
-8
-82
Net cash provided by operating activities
229
-9
-221
-39
Purchases of property and equipment
7
20
24
20
Purchases of in-process research and development and intangible assets
0
-
0
0
Acquisitions, net of cash acquired
-
-
0
-
Purchases of investments in debt securities
3
5
6
3
Sales of equity securities
-
-
1
-
Sales and maturities of debt securities
3
6
5
3
Other proceeds from investing activities
-
-
0
-
Net cash used in investing activities
-8
-19
-24
-20
Proceeds from the issuance of common stock
0
0
0
1
Cash paid for repurchases of common stock
176
126
0
0
Proceeds from debt, net
0
489
0
-
Repayments of debt
0
333
5
4
Transaction costs related to debt refinancing
0
5
0
-
Settlement of equity awards
0
21
2
0
Other
2
3
-
-
Net cash used in financing activities
-173
7
-5
-3
Net increase in cash and cash equivalents
48
-20
-252
128
Exchange differences
0
0
0
-2
Cash and cash equivalents at beginning of period
175
195
372
372
Cash and cash equivalents at end of period
222
175
195
445
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$122M
(87.69%↑ Y/Y)
Other current and
noncurrent liabilities
$73M
(-44.27%↓ Y/Y)
Deferred income taxes
$25M
(257.14%↑ Y/Y)
Stock-based compensation
$11M
(-21.43%↓ Y/Y)
Current inventories
-$4M
(81.82%↑ Y/Y)
Accounts receivable
-$3M
(80.00%↑ Y/Y)
Impairment of tangible and
intangible assets
$2M
Depreciation and
amortization
$2M
(-60.00%↓ Y/Y)
Accrued legal and
settlement expenses
$1M
(101.67%↑ Y/Y)
Amortization of debt issuance
costs
$1M
Impact from foreign
exchange movements
-$1M
(-120.00%↓ Y/Y)
Amortization of right-of-use
assets
$1M
(-80.00%↓ Y/Y)
Net cash provided by
operating activities
$229M
(44.94%↑ Y/Y)
Canceled cashflow
$17M
Net increase in cash
and cash...
$48M
Canceled cashflow
$181M
Other current and
noncurrent assets
$17M
(154.84%↑ Y/Y)
Other
$2M
Sales and maturities
of debt securities
$3M
(-72.73%↓ Y/Y)
Net cash used in
financing activities
-$173M
(-3360.00%↓ Y/Y)
Net cash used in
investing activities
-$8M
(52.94%↑ Y/Y)
Canceled cashflow
$2M
Canceled cashflow
$3M
Cash paid for
repurchases of common stock
$176M
Purchases of property and
equipment
$7M
(-58.82%↓ Y/Y)
Purchases of investments
in debt securities
$3M
(-50.00%↓ Y/Y)
something is missing
-$1M
Buy us a coffee
indivior-logo-svg
Indivior Pharmaceuticals, Inc. (INDV)
indivior-logo-svg
Indivior Pharmaceuticals, Inc. (INDV)